EP0920320A2 - Composition pharmaceutique injectable contenant l'acide ursodesoxycholique ou l'acide tauroursodesoxycholique, une base forte et du trometamol - Google Patents
Composition pharmaceutique injectable contenant l'acide ursodesoxycholique ou l'acide tauroursodesoxycholique, une base forte et du trometamolInfo
- Publication number
- EP0920320A2 EP0920320A2 EP96944084A EP96944084A EP0920320A2 EP 0920320 A2 EP0920320 A2 EP 0920320A2 EP 96944084 A EP96944084 A EP 96944084A EP 96944084 A EP96944084 A EP 96944084A EP 0920320 A2 EP0920320 A2 EP 0920320A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- acid
- composition according
- strong base
- ursodeoxycholic acid
- trometamol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Definitions
- the present invention relates to a new pharmaceutical composition based on ursodeoxycholic acid as such or conjugated with taurine.
- the invention relates to an injectable formulation of ursodeoxycholic acid or tauroursodeoxycholic acid to be administered intravenously, in particular by slow infusion.
- Ursodeoxycholic acid and tauroursodeoxycholic acid are drugs widely used in therapy as litholytics and in the treatment of various hepatic pathologies, such as hepatic cholestasis and primary biliary cirrhosis. It has now been found that the action of these drugs is particularly useful also in the treatment of liver pathologies in patients for whom oral administration is impossible or difficult.
- no injectable pharmaceutical formulation based on ursodeoxycholic acid or tauroursodeoxycholic acid is marketed, their preparation presenting problems due to the physicochemical properties of these active ingredients.
- Ursodeoxycholic acid is a weak acid practically insoluble in water; its solubility increases greatly in the presence of strong bases such as soda and potash.
- Aqueous solutions consisting only of ursodeoxycholic acid and a strong base are however not suitable for intravenous administration since even a small variation in the amount of strong base in the preparation leads to a consequent variation in the pH of the solution for injection which is often incompatible with intravenous administration.
- Tauroursodeoxycholic acid unlike ursodeoxycholic acid, is a strong acid, soluble in water, with a pKa of about 1.4. This high acidity is incompatible with intravenous administration; in this case also, one can resort to the addition of bases in the solution but the problems of the variation of the pH mentioned above are however not solved.
- ursodeoxycholic and tauroursodeoxycholic acids are detergent compounds and, for this reason, when added to an aqueous solution such as solution for intravenous infusion, cause foaming. It has now been found that the addition of trometamol ((tris-hydroxymethyl) - aminomethane) to an aqueous solution containing ursodeoxycholic acid or tauroursodeoxycholic acid and strong bases, leads to stable solutions, well buffered and suitable for intravenous administration.
- trometamol significantly decreases the formation and persistence of the foam which forms in the solution for intravenous infusion following the addition of the above preparation.
- the present invention therefore relates to an injectable aqueous composition which comprises ursodeoxycholic acid or tauroursodeoxycholic acid, a strong base compatible with intravenous administration and trometamol.
- the water used is suitable for injections.
- the formulation according to the invention comprises an amount of active principle, ursodeoxycholic acid or tauroursodeoxycholic acid, of between 1 and 30% (w / v), preferably between 5 and 20% (w / v), for example 10% (w / v).
- the strong base compatible with intravenous administration is preferably sodium or potassium hydroxide; such bases are used in an amount stoichiometrically equivalent with respect to the acid used.
- Trometamol is added in an amount of 0.01 - 2% (w / v), preferably in an amount of about 0.1% (w / v).
- the formulation according to the invention advantageously consists of an aqueous solution which comprises from 5 to 15% (w / v) of active principle (ursodeoxycholic acid or tauroursodeoxycholic acid), a stoichiometrically equivalent amount of strong base (sodium or potassium hydroxide ) and from 0.05 to 0.2% (w / v) of trometamol, ursodeoxycholic acid being the preferred active ingredient.
- active principle ursodeoxycholic acid or tauroursodeoxycholic acid
- strong base sodium or potassium hydroxide
- the aqueous injectable formulation which is the subject of the present invention preferably contains approximately 10% (w / v) of ursodeoxycholic acid, approximately 1% (w / v) of sodium hydroxide and approximately 0.1% (w / v) of trometamol.
- the formulation of the present invention is prepared by mixing the various components separately in distilled water and then bringing together the solutions / suspensions obtained. The solution is therefore properly filtered to remove any residues and sterilized.
- the solution is subdivided into ampoules or single-dose vials, optionally by operating under a nitrogen atmosphere, and, when used, diluted in the solution for intravenous infusion to be administered. by slow infusion. If it is desired in any case to use multi-dose containers, it might be advisable to add a bactericidal agent to the composition.
- a particularly advantageous solution for intravenous infusion is the physiological solution (usual, containing 0.9% sodium chloride).
- Physiological solutions for intravenous infusions containing the above composition are also an object of the present invention. More particularly, the invention also relates to a composition for intravenous infusions which comprises physiological solution, ursodeoxycholic acid or tauroursodeoxycholic acid, a strong base compatible with intravenous administration in an amount stoichiometrically equivalent with respect to the acid employed. , and trometamol. According to another of its aspects, the present invention relates to the use of ursodeoxycholic acid or tauroursodeoxycholic acid for the preparation of injectable formulations suitable for the treatment of hepatic pathologies of patients for whom the administration of oral medication is impossible.
- Said formulations are useful in subjects having undergone a transplant (for example liver, heart, marrow, kidney) for combating the hepatotoxic effects of the drugs which are normally administered following the transplant intervention; in subjects with hepatic impairment; in subjects whose feeding is carried out entirely parenterally; in subjects who have undergone a massive intestinal resection which provides for a prolonged fast; in newborns and children with hepatic cholestasis.
- a transplant for example liver, heart, marrow, kidney
- the duration of treatment by slow intravenous infusion of ursodeoxycholic acid or tauroursodeoxycholic acid, preferably administered by the formulation which is the subject of the invention varies according to the pathologies to be treated. In general, such a duration varies from 1 to 30 days, advantageously from 3 to 10 days, preferably from 5 to 7 days. If necessary, several treatment cycles can be carried out.
- the daily dose of active ingredient to be administered naturally varies according to the age and weight of the patient, as well as according to the type and severity of the pathology to be treated.
- the daily dose of active principle to be administered according to the present invention (expressed in mg of acid) is between 2 and 30 mg / kg of body weight, advantageously between 4 and 20 mg / kg, preferably between 8 and 15 mg / kg.
- the daily dose is between 500 and 2000 mg.
- Unit doses can therefore contain from 100 to 2000 mg of active ingredient
- Such unit doses after suitable dilution in solution for intravenous infusion, can be administered 1 or more times a day, as needed.
- the unit doses contain 250 or 500 mg of active principle (expressed in mg of acid), in volumes of 2.5 and 5 ml respectively.
- active principle expressed in mg of acid
- the ampoules thus obtained are capable of being diluted in a physiological solution and administered by slow infusion.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Exhaust Silencers (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI952763 | 1995-12-27 | ||
IT95MI002763A IT1282943B1 (it) | 1995-12-27 | 1995-12-27 | Composizione farmaceutica iniettabile__a base di acido ursodesossicoli co o tauroursodesossicolico |
PCT/FR1996/002083 WO1997024125A2 (fr) | 1995-12-27 | 1996-12-26 | Composition pharmaceutique injectable contenant l'acide ursodesoxycholique ou l'acide tauroursodesoxycholique, une base forte et du trometamol |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0920320A2 true EP0920320A2 (fr) | 1999-06-09 |
Family
ID=11372820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96944084A Ceased EP0920320A2 (fr) | 1995-12-27 | 1996-12-26 | Composition pharmaceutique injectable contenant l'acide ursodesoxycholique ou l'acide tauroursodesoxycholique, une base forte et du trometamol |
Country Status (7)
Country | Link |
---|---|
US (1) | US5955456A (fr) |
EP (1) | EP0920320A2 (fr) |
JP (1) | JP2000509013A (fr) |
AU (1) | AU1380397A (fr) |
CA (1) | CA2240266A1 (fr) |
IT (1) | IT1282943B1 (fr) |
WO (1) | WO1997024125A2 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596762B2 (en) | 2001-05-17 | 2003-07-22 | The Regents Of The University Of Colorado | Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis |
TWI232102B (en) | 2001-07-17 | 2005-05-11 | Shionogi & Co | A pharmaceutical formulation for injection |
US9295677B2 (en) * | 2008-02-26 | 2016-03-29 | Qing Bile Therapeutics Inc. | Polyhydroxylated bile acids for treatment of biliary disorders |
WO2021099973A1 (fr) | 2019-11-22 | 2021-05-27 | Shilpa Medicare Limited | Compositions injectables d'acide ursodésoxycholique |
KR20220123038A (ko) * | 2020-01-28 | 2022-09-05 | 실파 메디케어 리미티드 | 우르소데옥시콜산의 투여 방법 |
WO2022173043A1 (fr) * | 2021-02-15 | 2022-08-18 | 参天製薬株式会社 | Composition pharmaceutique à base d'eau contenant de l'acide ursodésoxycholique ou un sel de celui-ci |
TW202412751A (zh) * | 2022-08-09 | 2024-04-01 | 日商參天製藥股份有限公司 | 含有udca或其鹽之水性醫藥組合物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2521430A1 (fr) * | 1982-02-12 | 1983-08-19 | Pan Medica | Solution aqueuse d'acide ursodesoxycholique a usages therapeutiques, son procede de preparation et application au traitement des lithiases biliaires |
IL72420A (en) * | 1983-07-22 | 1987-10-30 | Hoffmann La Roche | Aqueous vitamin e solutions and their manufacture |
GB8706313D0 (en) * | 1987-03-17 | 1987-04-23 | Health Lab Service Board | Treatment & prevention of viral infections |
US5863550A (en) * | 1993-03-31 | 1999-01-26 | Tokyo Tanabe Company Limited | Cholestasis ameliorant |
-
1995
- 1995-12-27 IT IT95MI002763A patent/IT1282943B1/it active IP Right Grant
-
1996
- 1996-12-26 AU AU13803/97A patent/AU1380397A/en not_active Abandoned
- 1996-12-26 JP JP9524071A patent/JP2000509013A/ja active Pending
- 1996-12-26 CA CA002240266A patent/CA2240266A1/fr not_active Abandoned
- 1996-12-26 US US09/091,706 patent/US5955456A/en not_active Expired - Fee Related
- 1996-12-26 EP EP96944084A patent/EP0920320A2/fr not_active Ceased
- 1996-12-26 WO PCT/FR1996/002083 patent/WO1997024125A2/fr not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9724125A3 * |
Also Published As
Publication number | Publication date |
---|---|
ITMI952763A1 (it) | 1997-06-27 |
WO1997024125A2 (fr) | 1997-07-10 |
CA2240266A1 (fr) | 1997-07-10 |
JP2000509013A (ja) | 2000-07-18 |
IT1282943B1 (it) | 1998-04-02 |
US5955456A (en) | 1999-09-21 |
ITMI952763A0 (fr) | 1995-12-27 |
AU1380397A (en) | 1997-07-28 |
WO1997024125A3 (fr) | 1997-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2028142C1 (ru) | Фармацевтический раствор | |
KR890000700B1 (ko) | 지용성 약제물질을 함유한 수용액의 제조방법 | |
KR100368181B1 (ko) | 시각조직에의국부도포를위한누선특효유제 | |
EP1188437A2 (fr) | L'acide bêta-hydroxybutyrique ou l'acide acétoacétique ou leurs sels ou esters pour l'utilisation dans l'amélioration du fonctionnement cérébral | |
FR2731617A1 (fr) | Compositions pharmaceutiques nouvelles contenant du propofol | |
EP2307056B1 (fr) | Compositions pharmaceutiques aqueuses stables contenant du paracetamol | |
JP2003502363A (ja) | プロポフォールを含有する静脈内注射用麻酔剤組成物 | |
FR2515517A1 (fr) | Preparations stabilisees d'insuline et procede de production de celles-ci | |
FR2588189A1 (fr) | Composition pharmaceutique de type a transition de phase liquide-gel | |
CN1297527C (zh) | 还原型辅酶q水溶液的稳定组合物 | |
FR2466248A1 (fr) | Derives d'agents anti-inflammatoires non steroides, procede de preparation et compositions pharmaceutiques les contenant | |
BE1003647A5 (fr) | Composition pharmaceutique de nicardipine pour administration parenterale. | |
EP0920320A2 (fr) | Composition pharmaceutique injectable contenant l'acide ursodesoxycholique ou l'acide tauroursodesoxycholique, une base forte et du trometamol | |
JP2939082B2 (ja) | 安定なビタミンaパルミテート及びビタミンe類可溶化点眼剤 | |
FR2608428A1 (fr) | Composition therapeutique a base de cysteine, pour les complications diabetiques | |
FR2686513A1 (fr) | Compositions pharmaceutiques aqueuses de cromoglycate sodique. | |
US5276044A (en) | Leukotriene receptor antagonist and antihistamine complex pharmaceutical compositions | |
JPH06293639A (ja) | 安定なビタミンa類及びビタミンe類可溶化点眼剤 | |
CA1275247C (fr) | Procede de solubilisation, au moment de l'emploi, d'un principe actiflipophile dans une solution aqueuse, en vue de son administration par voie intraveineuse | |
FR2485371A1 (fr) | Nouvelle composition a usage therapeutique a base de lysine et d'arginine | |
KR101153250B1 (ko) | 글리시리진 고농도 제제 | |
JP3096052B2 (ja) | 脂質代謝調節剤 | |
FR2561522A1 (fr) | Solution injectable, notamment pour le traitement de la cetose et son procede de preparation | |
BE1007420A3 (fr) | Ampoules et solution de perfusion d'acides thioctique sous forme de sels solubles dans l'eau d'acide thioctique. | |
KR102478284B1 (ko) | 덱시부프로펜 함유 주사용 액상 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19980623 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SANOFI WINTHROP S.P.A. Owner name: SANOFI-SYNTHELABO |
|
17Q | First examination report despatched |
Effective date: 19991122 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20010709 |